Sickle Cell Disease Clinical Trials in Bethesda, Maryland

10 studies are recruiting for sickle cell disease in Bethesda, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease

   Background: Sickle Cell Disease (SCD) causes blood cells form a crescent shape. It is caused by a genetic mutation in the hemoglobin gene. People with SCD are at increased risk for illnesses like stroke, chronic pain, and heart problems, as well as decreased overall health and well-being. Researche…

   Stage

   Not phased

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institutes of Health Clinical Center (CC)

   See if you can join NCT05170412 on ClinicalTrials.gov

2. Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

   Background: Sickle cell disease (SCD) is a genetic disease that causes the body to produce abnormal ( sickled ) red blood cells. SCD can cause anemia and life-threatening complications in the lungs, heart, kidney, and nerves. People with SCD are also at increased risk of forming blood clots in the …

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Heart, Lung, and Blood Institute (NHLBI)

   See if you can join NCT05904093 on ClinicalTrials.gov

3. Blood Sampling for Research Related to Sickle Cell Disease

   This study will collect representative blood samples from healthy children and adults and from children and adults who have unique red blood cell features that are related to sickle cell disease. Sickle cell disease is a blood disease that limits the ability of red blood cells to carry oxygen throu…

   Stage

   Not phased

   Ages

   18 to 100

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

   See if you can join NCT00542230 on ClinicalTrials.gov

4. Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease

   The purpose of this research study is to look at genes and determine how they interact with each other to find changes that could explain why some people's immune systems may respond to blood transfusions. This response is called an alloimmune response. We strongly believe that when someone has an …

   Stage

   Not phased

   Ages

   2 to 99

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Human Genome Research Institute (NHGRI)

   See if you can join NCT06944067 on ClinicalTrials.gov

5. Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

   Background: Blood disorders like sickle cell disease and malaria affect many people around the world. Researchers want to learn more about blood disorders. To do this, they need to collect biological samples from people with blood disorders. They also need to collect samples from healthy people. Ob…

   Stage

   Not phased

   Ages

   18 to 70

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT03937817 on ClinicalTrials.gov

6. SCD Stem Cell Mobilization and Apheresis Using Motixafortide

   This study is being done to see if the study drug, motixafortide, is safe in participants with sickle cell disease (SCD). Investigators also want to see if the drug will help the body increase the number of stem cells that can be collected for possible future transplant use. PRIMARY OBJECTIVE * To …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   National Heart, Blood and Lung Institute-Cellular and Molecular Therapy Branch, Bethesda, Maryland

   Locations

   3 in total

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT06442761 on ClinicalTrials.gov

7. Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

   This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens. The goal is to aim for higher percentage of donor cell…

   Stage

   Phase 1

   Ages

   4 to 65

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Heart, Lung, and Blood Institute (NHLBI)

   See if you can join NCT07599176 on ClinicalTrials.gov

8. Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

   Background: Sickle cell disease (SCD) is an inherited disorder of the blood. SCD causes red blood cells (RBCs) to die early. This can lead to a shortage of healthy cells. SCD and other blood disorders can be managed with drugs or cured with a bone marrow transplant. Researchers want to know how lon…

   Stage

   EARLY_Phase 1

   Ages

   18 to 100

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Heart, Lung, and Blood Institute (NHLBI)

   See if you can join NCT06313398 on ClinicalTrials.gov

9. Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

   This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigili…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Center for Cancer and Blood Disorders, Bethesda, Maryland

   Locations

   16 in total

   Run by

   CSL Behring

   See if you can join NCT07224360 on ClinicalTrials.gov

10. Cooperative Assessment of Late Effects for SCD Curative Therapies

    Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births. Approximately 100,000 individuals are diagnosed with SCD in the United States. Mortality for children with SCD has decreased substantially over the past 4 decades, with >…

    Stage

    Not phased

    Ages

    4 to 65

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Locations

    5 in total

    Run by

    Vanderbilt University Medical Center

    See if you can join NCT05153967 on ClinicalTrials.gov